Top

Published in:

01-06-2019 | Kawasaki Disease | Original Article

Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review

Authors: Reo Tanoshima, Risa Hashimoto, Takanori Suzuki, Akira Ishiguro, Tohru Kobayashi

Published in: European Journal of Pediatrics | Issue 6/2019

Abstract

Kawasaki disease is an acute systemic vasculitis in children. Antiplatelet medicines are commonly used for Kawasaki disease to attenuate vasculitis and prevent thromboembolism; however, the mechanisms have not been elucidated. The objective of this study is to assess the effectiveness of antiplatelet medications for Kawasaki disease. We used Medline, Embase, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (Ichushi) from January 1947 to August 2018. Studies describing the platelet functions of antiplatelet drugs for Kawasaki disease were included. Twenty studies met the inclusion criteria. There were no randomized controlled trials. Seven studies compared platelet aggregation ability before and after treatment. Eight studies compared platelet aggregation with that in Kawasaki disease patients without treatment. Four studies compared aggregation among different types of antiplatelet drugs or at different doses. Antiplatelet medications administered in the studies included aspirin, flurbiprofen, dipyridamole, and choline salicylate. Methods for the measurement of platelet aggregation ability varied among studies. The groups with antiplatelet treatment tended to have a decreased platelet aggregation function. The statistical analyses were impossible due to insufficient quantitative data and heterogeneity among the studies.

Conclusion: The present systematic review revealed that there was insufficient evidence for the effectiveness of antiplatelet therapy for Kawasaki disease.

What is Known: • Antiplatelet therapy is widely used for Kawasaki disease to mitigate cardiac complications. • The mechanisms of antiplatelet therapy for Kawasaki disease are not clarified.
What is New: • This systematic review showed that the groups with antiplatelet treatment tended to have a decreased platelet aggregation function. • There is insufficient evidence for the effectiveness of antiplatelet therapy for Kawasaki disease.

Available only for authorised users

Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 379:1613–1620CrossRefPubMed

Yamada K, Fukumoto T, Shinkai A, Shirahata A, Meguro T (1978) The platelet functions in acute febrile mucocutaneous lymph node syndrome and a trial of prevention for thrombosis by antiplatelet agent. Acta Haematol Jap 41:113–124

Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS (2006) Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev (4):CD004175

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 135:e927–e999CrossRefPubMed

Inamo Y (1983) Studies on plasma thromboxane B, levels in patients with Kawasaki disease; as an indicator of coronary aneurysm formation. Acta Paediatr Jpn 25:230–237CrossRef

Igarashi T, Kazuhiro O, Cho H, Tsutomu I, Kinumaki H, Kataoka T, Noma S, Hishi T, Awa S, Kobayashi N, Yamanaka R, Sakurai M, Enomoto T, Hayashi Y (1984) Platelet aggregation and serum thromboxane B2 of low-dose and ultra low-dose aspirin for Kawasaki disease. J Jpn Pediatr Soc 88:1540–1544 article in Japanese

Shirahata A, Yamada K, Nojiri T, Miyaji Y, Iwasaki Y, Kan E, Izeki M, Fukumoto T (1979) Studies on aspirin administration in acute febrile mucocutaneous lymph node syndrome (MCLS), based on the antithrombotic effects of aspirin. Acta Paediatr Jpn 83:55CrossRef

Burns JC, Glode MP, Clarke SH, Wiggins J Jr, Hathaway WE (1984) Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 105:206–211CrossRefPubMed

Nakamura T (1985) Activated platelet in Kawasaki disease. J Jpn Pediatr Soc 89:1845–1860 article in Japanese

10.

Ichimaru T, Hamasaki Y, Hattori T, Tasaki H, Miyazaki S (1986) Aspirin therapy for Kawaseki disease (MCLS): action for arachidonic acid metabolism in platelets and vascular entothelium (part II clinical study). J Jpn Pediatr Soc 90:2223–2230 article in Japanese

11.

Sasai K (1988) Plasma PGE₂, TXA₂, and 6-keto PGF_1α levels in patients with Kawasaki disease. Arerugī 37:952–958 article in Japanese

12.

Fulton DR, Meissner C, Peterson MB (1988) Effects of current therapy of Kawasaki disease on eicosanoid metabolism. Am J Cardiol 61:1323–1327CrossRefPubMed

13.

Suzuki C, Yahata T, Okamoto-Hamaoka A, Fujii M, Yoshioka A, Niwa Y, Ikeda K, Nakamura A, Hamaoka K (2013) Utility of whole-blood aggregometry for evaluating anti-platelet therapy for Kawasaki disease. Pediatr Int 55:550–554CrossRefPubMed

14.

Taki M, Kobayashi M, Ohi C, Shimizu H, Goto K, Aso K, Murano K (2003) Spontaneous platelet aggregation in Kawasaki disease using the particle counting method. Pediatr Int 45:649–2652

15.

Yahata T, Suzuki C, Yoshioka A, Hamaoka A, Ikeda K (2014) Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J 78:188–193CrossRefPubMed

16.

Yokoyama T, Kato H, Ichinose E (1980) Aspirin treatment and platelet function in Kawasaki disease. Kurume Med J 27:57–61CrossRefPubMed

17.

Shibuya M, Maeda M, Hino Y, Kogo T, Hirayama T, Ogawa S, Watanabe Z, Yamamoto M, Ueda U (1986) Jpn J Clin Pharmacol Ther 17:153–154 article in JapaneseCrossRef

18.

Ohga K, Igarashi T, Nomai S, Hishi T, Iwata T, Kinumaki H, Awa S, Yanagawa Y, Enomoto T, Hayashi Y, Yamanaka T, Sakurai M, Kaku H, Yamanaka R, Miyashita T (1985) Low dose aspirin therapy for Kawasaki disease:evaluation of platelet function and incidence of coronary aneurysms. Prog Med 5:121–125 article in Japanese

19.

Hamasaki Y, Ichimaru T, Tasaki H, Miyazaki S (1988) Studies on the effect of long-term use of low dose aspirin in Kawasaki disease. Acta Paediatr Jpn 30:63–67CrossRefPubMed

20.

Sato T, Nagata M, Wada Y, Koike Y, Tetsuzawa O (1992) Anti-platelet therapy in patients with Kawasaki disease -comparison of platelet aggregation inhibitory effect between choline salicylate and aspirin. Jpn Pharmacol Ther 20:307–311 article in Japanese

21.

Inagaki M, Yamada K (1991) Inhibitory effects of high doses of intravenous γ-globulin on platelet interaction with the vessel wall in Kawasaki disease. Acta Paediatr Jpn 33:791–798CrossRefPubMed

22.

Hoshino A. (1985) Anti-platelet therapy for Kawasaki disease -especially for platelet aggregation function. Shonika-Rinsho. 38:118–124. article in Japanese

23.

Akagi T, Kato H, Inoue O, Sato N (1989) A study on the optimal dose of aspirin therapy in Kawasaki disease -clinical evaluation and arachidonic acid metabolism. Kurume Med J 37:203–208CrossRef

24.

STROBE statement. University of Bern. (2014). https://www.strobe-statement.org/index.php?id=strobe-home. Accessed 28 Dec 2018

25.

CONSORT Statement. (2018). http://www.consort-statement.org/. Accessed 28 Dec 2018

26.

Furusho K, Nakano H, Shinomiya K, Tamura T, Manabe Y, Kawarano M, Baba K, Kamiya T, Kiyosawa N, Hayashidera T, Hirose O, Yokoyama T, Baba K, Mori C (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 324:1055–1058CrossRef

27.

Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 96:1057–1061PubMed

28.

De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C (2018) The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J 8:49CrossRefPubMedPubMedCentral

29.

ClinicalTrials.gov. A multi-center, randomized to compare the efficacy of IVIG alone and IVIG plus high-dose aspirin in Kawasaki disease. US National Library of Medicine. (2018) https://clinicaltrials.gov/ct2/show/NCT02951234. Accessed 28 Dec 2018

Title: Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review
Authors: Reo Tanoshima
Risa Hashimoto
Takanori Suzuki
Akira Ishiguro
Tohru Kobayashi
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Kawasaki Disease
Kawasaki Disease
Kawasaki Disease
Published in: European Journal of Pediatrics / Issue 6/2019
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-019-03368-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Comparison of blind intubation with different supraglottic airway devices by inexperienced physicians in several airway scenarios: a manikin study

Comparison of Miller laryngoscope and UEScope videolaryngoscope for endotracheal intubation in four pediatric airway scenarios: a randomized, crossover simulation trial

Time to resolution of isolated antenatal hydronephrosis with anteroposterior diameter ≤ 20 mm

Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric non-alcoholic fatty liver disease

Correction to: Knowledge and practices regarding infant vaccination: results of a survey of French physicians

Relaxation-guided imagery reduces perioperative anxiety and pain in children: a randomized study